^{Zhitong Finance App News, Heyu-B (02256) issued an announcement. On November 11, 2026, the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) announced that a CSF-1R small molecule inhibitor, Beijemer® (English product name: PIMJETMI®, generic name: pimitinib hydrochloride capsules) has been approved by the US Food and Drug Administration (FDA) for systematic treatment and surgical resection may cause increased functional restrictions or serious complications} Symptoms of giant tenosynoid cytoma in adult patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.